Hennessy KM, Pollot BE, Clem WC, Phipps MC, Sawyer AA, Culpepper BK, et al
Growth Hormone Receptor cDNA microarray analysis identified GHR as abundantly upregulated following BPC-157 treatment, with dose-dependent increases reaching up to 7-fold elevation in both mRNA and protein levels (Chang et al., Molecules, 2014)
Bexacat (bexagliflozin tablets) Indication: Bexacat is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin
The consistency of positive findings across diverse experimental models and pathological conditions provides substantial support for the therapeutic potential of BPC-157
Benefits: Whos the Best Candidate for Peptide Therapy
Derived from a protective protein sequence, BPC-157 is commonly studied for its involvement in cellular healing processes and connective tissue support